Peer-reviewed veterinary case report
Cyclosporin A blood levels and treatment for dog skin allergy
By Steffan, J et al.·Published in Journal of veterinary pharmacology and therapeutics·2004·Novartis Animal Health·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Cyclosporin A pharmacokinetics and efficacy in the treatment of atopic dermatitis in dogs.
- Species:
- dog
Plain-English summary
A group of dogs with atopic dermatitis (a skin allergy condition) was treated with cyclosporin A (CsA) for 28 days to see how well it worked. The study found that while blood levels of the medication varied among dogs, there was no clear link between these levels and how much their skin improved. This suggests that regular blood tests to check CsA levels may not be needed for dogs receiving this treatment. Overall, the dogs showed improvement in their skin condition without the need for constant monitoring of the medication in their blood.
People also search for: dog skin allergy treatment · cyclosporin A for dogs · atopic dermatitis in dogs · dog itching treatment without blood tests
Abstract
A series of experiments was conducted to study cyclosporin A (CsA) pharmacokinetics in dogs and the factors influencing variability of blood concentrations. In a first study, influence of feeding on drug absorption and blood profile was evaluated. Administration of CsA as micro-emulsion (ME) formulation with food decreased the bioavailability by 22% and increased the individual variability of drug absorption. In a second study, pharmacokinetic profiles from laboratory fasted beagle dogs receiving orally CsA ME formulation were analyzed. CsA was measured in blood samples by high-performance liquid chromatography (HPLC, 34 profiles) and fluorescent polarization immunoassay (FPIA, 16 profiles). A two-compartment model with first-order absorption was used to calculate the pharmacokinetic parameters. Using FPIA, blood concentrations were 1.5 to 1.7 times higher than when using HPLC, but elimination half-life and MRT were similar. The coefficient of variation of key pharmacokinetic parameters ranged from 27 to 34% following HPLC assay. The same range of variation was obtained after FPIA assay. In a third study, in a clinical trial evaluating CsA for the treatment of canine atopic dermatitis, a single blood sample was collected in dogs which had received CsA for 28 days. No significant correlation was found between clinical improvement and CsA blood concentrations. Considering the large margin of safety of CsA in dogs, the limited inter-individual variability and the lack of correlation between blood concentrations and clinical response, routine monitoring of blood CsA does not appear necessary in dogs with atopic dermatitis.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/15305852/